<DOC>
	<DOCNO>NCT00583271</DOCNO>
	<brief_summary>The purpose prospective study measure clinical effectiveness EUS-guided CB subject , 50 chronic pancreatitis 50 pancreatic cancer , already undergoing celiac block clinical reason .</brief_summary>
	<brief_title>A Prospective Study EUS Guided Celiac Block</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Pancreatitis , Chronic</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<criteria>Patients chronic abdominal pain document chronic pancreatitis pancreatic cancer visceral malignancy undergo EUSguided CB ( purpose study ) eligible participate study . Patients chronic pancreatitis pancreatic cancer must document disease CT , ERCP , EUS . No evidence dementia alter mental status would prohibit give understand informed consent , evidence psychiatric risk would preclude adequate compliance protocol . Patient must provide sign write informed consent Patients previous celiac plexus block eligible study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>